Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007 Nov 16:8:451.
doi: 10.1186/1471-2105-8-451.

Peptide ligand screening of alpha-synuclein aggregation modulators by in silico panning

Affiliations

Peptide ligand screening of alpha-synuclein aggregation modulators by in silico panning

Koichi Abe et al. BMC Bioinformatics. .

Abstract

Background: alpha-Synuclein is a Parkinson's-disease-related protein. It forms aggregates in vivo, and these aggregates cause cell cytotoxicity. Aggregation inhibitors are expected to reduce alpha-synuclein cytotoxicity, and an aggregation accelerator has recently been reported to reduce alpha-synuclein cytotoxicity. Therefore, amyloid aggregation modulating ligands are expected to serve as therapeutic medicines.

Results: We screened peptide ligands against alpha-synuclein by in silico panning, a method which we have proposed previously. In this study, we selected as the target a very hydrophobic region known as the amyloid-core-forming region. Since this region cannot be dissolved in water, it is difficult to carry out the in vitro screening of its peptide ligand. We carried out 6 rounds of in silico panning using a genetic algorithm and a docking simulation. After the in silico panning, we evaluated the top peptides screened in silico by in vitro assay. These peptides were capable of binding to alpha-synuclein.

Conclusion: We demonstrated that it is possible to screen alpha-synuclein-binding peptides by in silico panning. The screened peptides bind to alpha-synuclein, thus affecting the aggregation of alpha-synuclein.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Scheme of in silico panning. In silico panning consists of two steps: a docking simulation and a genetic algorithm. The genetic algorithm consists of selection, crossover and point mutation. This figure shows one example of a genetic algorithm.
Figure 2
Figure 2
Distribution of the docking energy. The ranks of the peptide ligands in each generation are shown on the X- and Y-axes. The Z-axis shows the docking energies, which were calculated as follows: (a) docking total energy = electrostatic energies + van der Waals energies + conformational energy of the ligand; (b) interaction energy = total docking energy - conformational energy of the ligand. At the 1st to the 3rd generation, the peptides were evaluated by the total docking energy (a); at the 4th to the 6th generation, the peptides were evaluated by the interaction energy (b).
Figure 3
Figure 3
Time course of α-synuclein fibril formation. The Y-axis shows the normalized fluorescence intensity of Thioflavin T at 482 nm. 100% is the final fluorescence intensity of α-synuclein without peptide. The samples contained the following: α-synuclein (140 μM) without peptide, (Circle); QSTQ, (Black diamond); GSQQ, (Empty diamond); SQTQ (Black square); AQTQ, (Empty square). All peptide concentrations were 700 μM.
Figure 4
Figure 4
Light scattering assay. The Y-axis shows the normalized optical density at 330 nm. 100% is the optical density at 330 nm of α-synuclein without peptide.

Similar articles

Cited by

References

    1. Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M. alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proc Natl Acad Sci U S A. 1998;95:6469–6473. doi: 10.1073/pnas.95.11.6469. - DOI - PMC - PubMed
    1. Conway KA, Harper JD, Lansbury PT. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat Med. 1998;4:1318–1320. doi: 10.1038/3311. - DOI - PubMed
    1. Conway KA, Lee SJ, Rochet JC, Ding TT, Williamson RE, Lansbury PT., Jr. Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc Natl Acad Sci U S A. 2000;97:571–576. doi: 10.1073/pnas.97.2.571. - DOI - PMC - PubMed
    1. Greenbaum EA, Graves CL, Mishizen-Eberz AJ, Lupoli MA, Lynch DR, Englander SW, Axelsen PH, Giasson BI. The E46K mutation in alpha-synuclein increases amyloid fibril formation. J Biol Chem. 2005;280:7800–7807. doi: 10.1074/jbc.M411638200. - DOI - PubMed
    1. Hashimoto M, Hsu LJ, Sisk A, Xia Y, Takeda A, Sundsmo M, Masliah E. Human recombinant NACP/alpha-synuclein is aggregated and fibrillated in vitro: relevance for Lewy body disease. Brain Res. 1998;799:301–306. doi: 10.1016/S0006-8993(98)00514-9. - DOI - PubMed

LinkOut - more resources